[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atyr Pharma Inc (ATYR)

Atyr Pharma Inc (ATYR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,389
  • Shares Outstanding, K 98,051
  • Annual Sales, $ 190 K
  • Annual Income, $ -74,120 K
  • EBIT $ -78 M
  • EBITDA $ -78 M
  • 60-Month Beta 0.52
  • Price/Sales 250.80
  • Price/Cash Flow N/A
  • Price/Book 0.83
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.79
  • Most Recent Earnings $-0.11 on 05/15/26
  • Next Earnings Date 08/06/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 227.34% (-121.77%)
  • Historical Volatility 94.89%
  • IV Percentile 43%
  • IV Rank 13.87%
  • IV High 1,155.84% on 10/08/25
  • IV Low 77.82% on 01/14/26
  • Expected Move (DTE 1) 0.0850 (16.48%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 192
  • Volume Avg (30-Day) 437
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 40,857
  • Open Int (30-Day) 36,633
  • Expected Range 0.4309 to 0.6009

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 2
  • High Estimate $-0.14
  • Low Estimate $-0.16
  • Prior Year $-0.22
  • Growth Rate Est. (year over year) +31.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4423 +16.64%
on 06/17/26
0.6998 -26.28%
on 07/07/26
+0.0681 (+15.21%)
since 06/16/26
3-Month
0.3950 +30.61%
on 05/13/26
1.0500 -50.87%
on 05/06/26
-0.3146 (-37.88%)
since 04/16/26
52-Week
0.3950 +30.61%
on 05/13/26
7.2904 -92.92%
on 07/28/25
-5.3241 (-91.17%)
since 07/16/25

Most Recent Stories

More News
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

  Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol...

ATYR : 0.5159 (-3.44%)
Atyr Pharma: Q1 Earnings Snapshot

Atyr Pharma: Q1 Earnings Snapshot

ATYR : 0.5159 (-3.44%)
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

  Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in...

ATYR : 0.5159 (-3.44%)
aTyr Pharma to Participate in Upcoming Investor Conferences

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary...

ATYR : 0.5159 (-3.44%)
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting.President...

ATYR : 0.5159 (-3.44%)
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic,...

ATYR : 0.5159 (-3.44%)
Atyr Pharma: Q4 Earnings Snapshot

Atyr Pharma: Q4 Earnings Snapshot

ATYR : 0.5159 (-3.44%)
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis.  Phase 2 EFZO-CONNECT™...

ATYR : 0.5159 (-3.44%)
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class...

ATYR : 0.5159 (-3.44%)
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary...

ATYR : 0.5159 (-3.44%)

Business Summary

aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.

See More

Key Turning Points

3rd Resistance Point 0.5843
2nd Resistance Point 0.5629
1st Resistance Point 0.5394
Last Price 0.5159
1st Support Level 0.4945
2nd Support Level 0.4731
3rd Support Level 0.4496

See More

52-Week High 7.2904
Fibonacci 61.8% 4.6564
Fibonacci 50% 3.8427
Fibonacci 38.2% 3.0290
Last Price 0.5159
52-Week Low 0.3950

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.